Advertisement
Pharma/Biotech News
Subscribe to Pharma/Biotech News
View Sample

FREE Email Newsletter

Daily news and top headlines for drug research professionals

BMS to Collaborate on Immunotherapy Evaluation

November 24, 2014 1:01 pm | News | Comments

BMS and Five Prime Therapeutics Inc. announced that they have entered into an exclusive clinical collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of immunotherapy drugs. Read more...       

BioMarin Pharma Offers About $680M for Prosensa

November 24, 2014 12:41 pm | News | Comments

The company also said it will make two approximately $80 million milestone payments to Prosensa shareholders. Read more...                       

Amgen-Sponsored Gastric Cancer Studies Terminated

November 24, 2014 11:01 am | News | Comments

Amgen announced the termination of all Amgen-sponsored clinical studies of rilotumumab in advanced gastric cancer,  including the Phase 3 RILOMET-1 and RILOMET-2 studies. Read more...                                 

Advertisement

EU Approves Novartis' Signifor Drug for Rare Hormonal Disorder

November 24, 2014 10:38 am | News | Comments

Novartis announced today that the European Commission has approved Signifor (pasireotide) as a new long acting release formulation for once monthly intramuscular injection to treat adult patients with acromegaly for whom surgery is not an option or has not been curative and who are inadequately controlled on treatment with a first-generation somatostatin analogue (SSA).  Read more...

Health Care M&A Leads Global Deal Surge

November 24, 2014 9:17 am | by Linda A. Johnson and Steve Rothwell, AP Business Writers - Associated Press | News | Comments

In a big year for deal making, the health care industry is a standout. Large drugmakers are buying and selling businesses to control costs and deploy surplus cash. A rising stock market, tax strategies and low interest rates are also fueling the mergers and acquisitions. Read more...

Neurotrope: Last Patient Dosed in Phase 2a Alzheimer's Study

November 21, 2014 11:41 am | News | Comments

Neurotrope, Inc. announced that the last patient has been dosed in its Phase 2a clinical trial of Bryostatin-1 for the treatment of patients with Alzheimer's disease (AD). The trial is being conducted under an Investigational New Drug (IND) application filed by the Company's licensor, the Blanchette Rockefeller Neuroscience Institute (BRNI). Read more...

FDA Approves New, Hard-to-Abuse Hydrocodone Pill

November 21, 2014 11:27 am | by Matthew Perrone, AP Health Writer - Associated Press | News | Comments

Federal health regulators on Thursday approved the first hard-to-abuse version of the painkiller hydrocodone, offering an alternative to a similar medication that has been widely criticized for lacking such safeguards. Read more...

Soaring Generic Drug Prices Draw Senate Scrutiny

November 21, 2014 11:10 am | by Matthew Perrone, AP Health Writer - Associated Press | News | Comments

Some low-cost generic drugs that have helped restrain health care costs for decades are seeing unexpected price spikes of up to 8,000 percent, prompting a backlash from patients, pharmacists and now Washington lawmakers. Read more...

Advertisement

HIV/AIDS Drugs Could Be Repurposed to Treat AMD

November 21, 2014 11:01 am | by Ann Blackford, University of Kentucky | News | Comments

A study published in the journal Science by an international group of scientists, led by the laboratory of Dr. Jayakrishna Ambati, professor and vice chair of the Department of Ophthalmology & Visual Sciences at the University of Kentucky, reports that HIV/AIDS drugs that have been used for the last 30 years could be repurposed to treat AMD. Read more...

AbbVie Acquires Manufacturing Facility in Singapore

November 21, 2014 10:04 am | News | Comments

The facility will expand the company's global operations for small molecule and biologics manufacturing. Read more...                        

BI's IPF Drug Gains Positive Opinion in Europe

November 21, 2014 9:52 am | News | Comments

Boehringer Ingelheim's announced that its idiopathic pulmonary fibrosis drug gained a positive opinion in Europe. Read more...                      

Shire Relocates 500 Jobs to Massachusetts

November 20, 2014 1:54 pm | News | Comments

Shire is transferring 500 jobs to Massachusetts. Read more...                                  

Early Statin Use May Give Long-Term Heart Benefits

November 20, 2014 10:06 am | by Marilynn Marchione, AP Chief Medical Writer - Associated Press | News | Comments

Taking a cholesterol-lowering drug for five years in middle age can lower heart and death risks for decades afterward, and the benefits seem to grow over time, a landmark study finds. Doctors say it's the first evidence that early use of a statin can have a legacy effect, perhaps changing someone's odds of disease for good. Read more...

Advertisement

Camurus, Braeburn Pharmaceuticals Sign Exclusive License for Opioid Treatment

November 20, 2014 9:15 am | News | Comments

Camurus and Braeburn Pharmaceuticals announced that they have entered into an exclusive license agreement for Camurus' weekly and monthly subcutaneous buprenorphine injection products (CAM2038) for the treatment of opioid addiction and pain. Read more...   

Regeneron, Sanofi: New Positive Results for Cholesterol-Lowering Drug

November 20, 2014 9:06 am | News | Comments

Regeneron Pharmaceuticals, Inc. and Sanofi announced new detailed positive results from six Phase 3 ODYSSEY trials that showed alirocumab significantly reduced low-density lipoprotein cholesterol (LDL-C, or "bad" cholesterol). Read more...

Royalty Pharma Pays $3.3B for Cystic Fibrosis Royalties

November 19, 2014 1:51 pm | News | Comments

Royalty Pharma announced its acquisition of royalties on Vertex Pharmaceuticals' cystic fibrosis treatments owned by Cystic Fibrosis Foundation Therapeutics' ("CFFT"), an affiliate of the Cystic Fibrosis Foundation, for a cash payment of $3.3 billion. Read more...

$2.6B: Cost to Develop, Win Marketing Approval for New Drug

November 19, 2014 1:35 pm | News | Comments

Developing a new prescription medicine that gains marketing approval, a process often lasting longer than a decade, is estimated to cost $2,558 million, according to the Tufts Center for the Study of Drug Development. Read more...

Janssen Seeks European Approval of Chronic Inflammatory Disease Drug

November 19, 2014 10:16 am | News | Comments

Janssen submitted an application for European approval regarding a drug intended to treat chronic inflammatory disease of the spine. Read more...                    

Cardiome Finds Distributor for AFib Drug in South Africa

November 19, 2014 9:59 am | News | Comments

Cardiome entered into a new partnership with Pharmacare Ltd to sell and distribute its AFib drug in South Africa. Read more...                     

New Insight Into Cells Could Lead to Better Drugs

November 19, 2014 9:11 am | News | Comments

Researchers investigated how different types of immune cells communicate with each other – and how they kill cancerous or infected cells. Read more...                   

Pfizer's Meningococcal Group B Vaccine Is Now Available

November 18, 2014 1:58 pm | News | Comments

Pfizer Inc. announced that Trumenba (Meningococcal Group B Vaccine) is now available for order by healthcare providers in the United States. Read more...

Strategy: Physicians Prescribe More Generics, Less Brand Name Drugs

November 18, 2014 1:19 pm | News | Comments

Programming electronic health records to make generic drugs the default choice when physicians write prescriptions may offer one way to reduce unnecessary spending and improve health care value in the face of spiraling U.S. health expenditures, according to a new study. Read more...

Merck's Cholesterol-Lowering Drug Reduces Heart Problems

November 18, 2014 10:22 am | News | Comments

Merck, known as MSD outside the United States and Canada, announced that the investigational IMPROVE-IT study met its primary and all secondary composite efficacy endpoints.  Read more...

Novartis' Drug Could Change Course of Heart Failure for Patients

November 18, 2014 9:57 am | News | Comments

New data on Novartis' investigational medicine, LCZ696, for patients with heart failure with reduced ejection fraction (HFrEF) shows it has the potential to change the course of the disease for patients. Read more...

Actavis to Buy Allergan for $66B

November 17, 2014 2:34 pm | by Tom Murphy - AP Business Writer | News | Comments

Actavis will pay $66 billion to buy fellow drugmaker Allergan in a deal that could finally end a months-long takeover push from Valeant Pharmaceuticals. Read more...                

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading